Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796250 | 0.84 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2793131 | 0.79 | LMNA (0.58) | LMNACA12CA1CA2CA3 | |
| SCHEMBL23488112 | 0.77 | PARP10 (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL323591 | 0.74 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1318890 | 0.74 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10916558 | 0.73 | SMN1; SMN2 (0.57) | LMNACA12CA1CA2CA3 | |
| SCHEMBL75124 | 0.73 | MAPT (0.62) | LMNACA12CA1CA2CA3 | |
| SCHEMBL6989879 | 0.73 | LMNA (0.55) | LMNACA12CA1CA2CA3 | |
| SCHEMBL23119878 | 0.73 | SMN1; SMN2 (0.56) | LMNACA12CA1CA2CA3 | |
| SCHEMBL23488111 | 0.73 | NR4A2 (0.54) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4396354-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2024-07-10 | — | — | EP | disclosed |
| EP-4367125-A1 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4359380-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL) METHYL)BENZYL) AMINO)ISOINDOLINE-1,3-DIONE | Celgene Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024073745-A1 | INHIBITORS OF EGFR OR HER2 AND METHODS OF USE | ARBELLA THERAPEUTICS, LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023283434-A9 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023201005-A2 | HYDROPHOBIC POLYMER AEROGELS | AEROGEL TECHNOLOGIES, LLC (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023196342-A1 | α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11730810-B2 | Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2023139145-A1 | SAPONIN-BASED ADJUVANTS AND VACCINES | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) | 2023-07-27 | — | — | WO | disclosed |
| WO-2010059241-A2 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010057006-A1 | AZAQUINOLINONE DERIVATIVES AND USES THEREOF | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2073816-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-0651761-B1 | METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES | BIONEBRASKA INC (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1170300-A1 | Method for modification of recombinant polypeptides | BIONEBRASKA, INC. (US) | 2002-01-09 | — | — | EP | disclosed |
| US-5656456-A | Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof | BIONEBRASKA, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5635371-A | Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof | BIONEBRASKA, INC. (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0651761-A1 | METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES | BIONEBRASKA, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994001451-A2 | METHOD FOR MODIFICATION OF RECOMBINANT POLYPEPTIDES | BIONEBRASKA, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730810-B2 | Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response | CD4, MYD88, STING1 | LMNA 4799/4885CA12 3645/4885CA1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.